ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Demographic and clinical characteristics of initial patients receiving amyloid-targeting treatments in the United States after regulatory approval.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Further data to address the Alzheimer's coverage with evidence development questions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Descriptive Analysis of Retrospective Observational Real-World Evidence of a Monoclonal Anti-Amyloid Therapy Program in a Wide Catchment Specialty Memory Clinic.Neurology and therapy · 2026Article
- Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Patient views on blood-based biomarker tests for Alzheimer's disease in primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Real-world evidence from 50,000 online participants using MoCA-XpressO for cognitive prescreening.Scientific reports · 2026Article
- Demographic and clinical characteristics of initial patients receiving amyloid-targeting treatments in the United States after regulatory approval.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Dementia Care Specialists' Perspectives of Diagnosis and Early Psychosocial Care: A Qualitative Analysis of Focus Groups in Two Large Academic Medical Centers.Journal of aging research · 2025Article
- Eligibility for anti-amyloid treatment in a multiethnic community-based study.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Medical comorbidities of patients receiving amyloid-targeting treatments in a memory clinic.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThree treatments for Alzheimer's disease have been approved in the United States. Data are lacking on the characteristics of the initial treatment recipients.
methodsWe identified treatment recipients in the full Medicare fee-for-service data for 2021 to 2023. We compared their age, sex, race/ethnicity, dual eligibility, comorbidities, and median household income and educational attainment in their residence's ZIP Code Tabulation Area (ZCTA) to those of the overall Medicare population aged 65+.
resultsTreated patients were more likely to be non-Hispanic White (89% vs 82%) and less likely to be dually eligible (1% vs 8.8%). Average median household income ($97,136 vs $84,449) and proportion of residents with at least a bachelor's degree (41% vs 31%) were higher in treated patients' ZCTAs. DISCUSSION: The first patients receiving amyloid-targeting treatment represent a more privileged subset. While needing to be confirmed with more data, these results point to the need for efforts to make access more equitable. HIGHLIGHTS: Little is known about the initial 924 patients receiving amyloid-targeting treatments in the United States from 2021 to 2023. They were more likely to be White and less likely to be dually eligible than the Medicare population. They resided in wealthier and more highly educated areas. Comorbidity burden was similar to that observed in clinical trials. Those initial results point to the need to improve equitable access to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.